Report in 1Q 2013 data of a Phase II clinical trial, conducted by Inovio's collaborator ChronTech Pharma AB treating hepatitis C virus with a DNA vaccine delivered with INO's proprietary electroporation delivery system in conjunction with a drug regiment.
INO expects to publish a paper on it's HIV study Phase I in H1 2013. CEO said that the results will be out earlier though.
The company also expects to have additional data in 2Q 2013 from it's influenza study on the elderly population over 65.
As for a target price, you should consider many factors. If you are familiar with stage development pharmaceutical companies, you know how positive results can totally change the evaluation of such companies. The difference here is that Inovio is not a one-drug company and positive results for one of its vaccines can strength the possibilities of success for all the other of its wide pipeline.